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Depression is a highly debilitating syndrome that affects the global population and is associated 
with disabilities and suicide. Depression remains poorly studied and is often treatment resistant 
and recurrent. Thus, development of new therapies and drugs is needed in the field. Animal models 
are indispensable for translational biological psychiatry, and may advance the study of depression. 
While poor understating of psychiatric disorders (including depression) is slowing down further 
progress in the field, novel approaches continuously emerge that may help untangle disorder 
heterogeneity and blurred categories of contemporary diseases classification systems. Dividing 
core symptoms into easily translatable phenotypes is an effective way to reevaluate current 
paradigms. Also, other, more deep and complicated approaches and theories based on the 
endophenotype paradigm, such as ‘cross-species trait genetic’ and ‘domain interplay concept’ do 
continuously emerge to improve current paradigms and drug screening. 
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With over 300 million affected people globally, major depression is the largest cause of 
human disability1. Depression is a highly heterogeneous clinical disorder the diagnosis of which 
is complicated due to broad phenomenological criteria and poorly understood neurobiological 
bases2-5. Associated with mood-, appetite-, sleep-, energy-, cognitive-, motor- and other deficits, 
depression symptoms may be grouped into several distinct neuropathological subtypes2(Table 1). 
Thus, clinical or preclinical modeling of depression is complicated by the fact that we deal with 
multiple ‘depressions’6-8.  
Another problem is that approximately 1/3 of depressed patients are treatment-resistant, 
and the disorder has high rates of recurrence9-13 and comorbidity with other brain illnesses14-15 
(Fig. 1). Furthermore, most existing antidepressant drugs have slow-onset action (weeks or 
months), and other available therapies, such as electro-convulsive therapies have significant side-
effects (e.g., amnesia)5. Thus, development of new therapeutic methods and antidepressants that 
address these limitations are desperately needed in the field5, 16. However, this becomes a 
particularly challenging task, given the lack of pathophysiological understanding of this disease. 
Indeed, the most widely accepted monoamine imbalance hypotheses17-18 cannot account for 
limitations discussed above (delayed effects, treatment resistance), and recently proposed 
‘inflammation’ hypotheses19-21 do not account for major neurotransmitter deficits common for 
depression. Thus, further progress is urgently needed in the field, including conceptually new, 
paradigm-shift approaches and theories16, 22-23.  
Animal (experimental) models are an indispensable tool in translational and neuroscience 
research23-24, relying on several well-recognized validity criteria, such as face (similarity of 
phenotypes), construct (similarity of neurobiological mechanisms) and predictive (similarity of 
treatment responsivity) validity10, 25-27. For clear ethical, practical and historical reasons, most 
research utilizes rodents to study depression and other affective disorders10, 28-34 (Fig. 2). Rodent 
models of depression are relatively well-established, and target different aspects of depression 
(Table 2), including stress35-40, genetics41-49, inflammation50-53 and drug responses54-56. Here, we 
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recognize multiple challenges currently faced by the field of experimental depression models. The 
present report is a multi-lab effort, lead by the International Stress and Behavior Society (ISBS) 
Special Panel on experimental and translational depression models.  
Many animal models of depression display homologous physiological and neurochemical 
responses. For example, stress-based models, such as chronic unpredictable stress, chronic social 
defeat stress, chronic restraint, prolonged social isolation and single prolonged stress, not only 
result in depression and anxiety-like behavioral phenotypes, as well as memory and sleep 
disturbances, but also increase plasma models of molecular biomarkers (e.g., interleukins IL-1β, 
IL-6, TNF-α) and decrease neurotrophins (e.g., BDNF and NGF) in the brain – the effects which 
can be reversed by antidepressant treatment23, 35-40, 57-64. Since stress is the most common factor of 
depression onset and progression26, 57, high face and construct validity, predictive power and 
relative simplicity make stress-based models widely used to model depression23, 65. 
While genetic vulnerability plays a role in 35–40% of variance in depression66, human 
genetic analyses often fail to identify reproducible genetic loci that contribute significantly to 
depression67. Indeed, reflecting the multi-factorial nature of depression, recent genetic studies 
reveal deep connections between psychiatric disorders, including depression, and immune factors, 
neuronal signaling, synaptic density and histone cascades, suggesting the presence of larger risk 
clusters in these pathways68. Genetic rodent models indicate the role of serotonergic41-44, 
noradrenergic45-46, 69-70, dopaminergic71-72, opioid73-74, GABA-ergic10, 75-76 and glutamatergic77-80 
systems in depression-like behavior. However, translation of these models into human depression 
faces difficulties due to restriction of knockouts to one gene and, at the same time, simultaneous 
involvement of most core neurotransmitter systems in animal depression-associated behavior. 
Moreover, depression is also recognized as a result of gene x environment interactions (GxE), 
acting as a susceptibility and a trigger, respectively81-82. 
There are also other behavioral paradigms that are tightly related to depression-like 
behavior. For example, sickness behavior (Table 2) is associated with depressive behavior and 
usually evolves as acute sickness reaction to an inflammatory agent, followed by gradually 
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increasing depression-like behavior, including social withdrawal and motor retardation31. This 
effect involves cytokine signaling pathways31 and can be induced by a wide range of agents, 
including polysaccharide (LPS)83-89, viral mimetic polyriboinosinic-polyribocytidylic acid (Poly 
I:C)90, interferon (IFN)-α91-93 and bacillus Calmette-Guerin (BCG)94-95. Some overlaps between 
drug withdrawal and depression also exist96 and have been reported in rodents for cocaine, 
amphetamine, ethanol, morphine and nicotine54-56 (also note hypomania following antidepressant 
discontinuation both in clinical practice and animal models97-98). 
Now that there are good models of inducing depression in animals, the next logical 
question is whether we have reliable methods to assess animal depression-like behaviors? This 
question is also important because antidepressant drug discovery heavily relies on such tests. The 
core depression-related symptoms that can be accessed in rodents include anhedonia, eating and 
sleep disturbances, agitation or retardation of motor activity, cognitive deficits, energy loss, 
despair as well as neuroimmune and neuroendocrine disturbances10, 24, 99-116. However, these 
symptoms are not specific to depression, and can often occur in other psychiatric and other 
diseases. For example, the forced swim test (FST)114, 116-117 and  the tail suspension test (TST)112, 
118 are commonly used to access behavioral despair in rodents. However, albeit considered one of 
the main depression-like states, despair is not unique for depression and can be observed in other 
models119. Thus, a wider range of tests and/or complex batteries of behavioral tests that address 
distinct domains should be used to increase rates of successful antidepressant drugs determination.  
2. Non-rodent models of depression 
While rodent depression-like states and effects of antidepressants have long been 
recognized, many other model species exist that can be used to target evolutionarily conserved 
depression-related states. For example, non-human primates can bridge a gap between rodent and 
human models120-121, whereas zebrafish models can provide novel complementary data (in addition 
to rodent models) that may untangle high heterogeneity of depression by focusing on its core, 
evolutionarily conserved roots (Table 3). Common models of depression in non-human primates 
involve maternal122-123 or social separation 124-125 and reflect various aspects of human 
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depression126, such as despair, anhedonia and lethargy127. Such models are validated 
pharmacologically, and, interestingly, antidepressants seem to have similar time course to that 
observed clinically (unlike in some rodent models)128-129. Other drugs, including amphetamine and 
ethanol, exert antidepressant effects in non-human primates127, 130, whereas g-methyl-p-tyrosine or 
reserpine reduce social interactions and locomotion, as well as induce anhedonia-like lack of 
environmental interaction126, 131. Interestingly, depressive behaviors can occur in macaques 
spontaneously132, strikingly reproducing human depression. Likewise, neurochemical alterations 
in primate oxytocin, monoamines and their metabolites also resemble alterations observed in 
depressed patients133-139. Finally, non-human primates are also used to model depressive behavior 
in chronic stress140 and cytokine-induced depression141. 
Among lower vertebrates, zebrafish represent an interesting model organism to study 
complex CNS states142-146, including anxiety, addiction, autism, obsessive-compulsive states and 
depression142-146. Similarly to rodents, zebrafish depression-like states can be induced using stress, 
genetic or pharmacological manipulations147 (Table 3). For instance, zebrafish chronic stress 
exposure elevates anxiety-related behavior, increases whole-body cortisol, IL-1β, IL-6, adenosine, 
mr, grα, grβ, bdnf in telencephalon, CRH, calcineurine, pCREB levels in brain, alters dendritic 
spines, reduces weight, and lowers dopamine and 5-HIAA levels148-153. Importantly, many of these 
effects can be corrected by antidepressant treatment151, thereby showing highly homologous 
chronic stress responses to those observed in rodents and humans. Moreover, zebrafish depression 
models differ from those in mammals (e.g., bdnf/BDNF expression is often reduced in human and 
rodent depression models151),  therefore providing not a “smaller mouse” model, but a truly 
complementary tool to study specific aspects of depression pathogenesis in-vivo.  
While zebrafish possess some features that may cumulatively surpass advantages those of 
rodents154, its use in biological psychiatry is still developing, and therefore meets obstacles, 
challenges and skepticism. For example, it is still unclear how to properly distinguish zebrafish 
anxiety-like and depression-like phenotypes (if they are distinct at all)147, thus necessitating further 
7 
 
deep phenotyping and developing of tests that can access more precisely various features of 
experimental depression. 
3. Theories of depression pathogenesis and new trends 
From 1948, when serotonin was first isolated, purified and identified as a monoamine155-
156, and 1969, when it was first linked to depression155, the field has clearly moved a long way. For 
example, there is a great diversity of serotonin receptors that can produce different effects 
depending on neuron type and cellular localization. Since 5-HT1A agonists exert anxiolytic and 
antidepressant properties, it has been hypothesized that this type of receptor plays a role in 
developing depression. Postnatal antidepressant treatment can result in anhedonia, anxiety, 
increased (learned?) helplessness and other depression-related disturbances in adult rodents113, 157-
158, whereas 5-HT1A knockout in mice display antidepressant-like behavior29, 159-160 and serotonin 
transporter knockout rodents display anxiety-like and higher stress vulnerability41-44. 
Another hypothesis of depression is based upon inflammation caused by stress, as the 
expression of IL-1β, IL-6, TNF-ɑ and IFN-ɣ genes were significantly higher in patients with major 
depression161-162. Furthermore, elevated stress hormones can impact the expression of several 
neurotrophic factors, thus influencing on neuroplasticity, which is impaired in depressed 
patients161. Likewise, the hypothalamic–pituitary–adrenal (HPA) axis function is altered in 
depressed patients as well as in depressed rodent models, and reversed by antidepressant 
treatment161. Likewise, disturbances of affective spectrum can occur after exposure to 
inflammatory agents (e.g., lipopolysaccharide (LPS)83-86, viral mimetic polyriboinosinic-
polyribocytidylic acid90 and some autoantibodies163) or as a result of genetic manipulations of 
pro/anti-inflammation-related genes (e.g., IL-1051-53 and TNF-α knockout models50). In line with 
this, anti-inflammatory agents can reduce depressive symptoms in humans164 and animals. For 
example, an anti-inflammatory microglia inhibitor antibiotic minocycline prevents LPS-induced 
increase in cytokines expression and indoleamine 2,3 dioxygenase (IDO, the tryptophan-degrading 
enzyme), blocking both sickness- and depression-like behavior in mice165. Interestingly, IDO 
antagonist 1-methyl-D,L- tryptophan exposure does not alter LPS- and Bacillus Calmette-Guerin 
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(BCG)-induced proinflammatory cytokines and sickness-like, but reduces depression-like 
behavior95, 165, suggesting that novel anti-inflammatory agents can be screened for further use in 
depression treatment. 
Aberrant GABA neurotransmission has also been linked to depression, as major depression 
is associated with GABRA1, GABRA5, GABRA6 and GABRG2 genes, and childhood mood 
disorders - with a male-specific polymorphism of the GABRD gene161. Consistent with this, major 
depression is generally accompanied by reduced GABA levels, which can be restored by 
conventional antidepressant treatments161. Interestingly, genetic modifications of GABA-
associated proteins may affect anxiety and depression in different ways, since the glutamate 
decarboxylase (GAD65) knockout and GABA-B1  knockout display high anxiety-like but lower 
depression-like behaviors10, 75-76, thereby providing a potentially valuable tool to dissect these two 
commonly comorbid (and frequently overlapping) conditions. 
The reduction in astrocyte function and increased microglial activity and related markers 
are key features of major depression166-168. Indeed, astrocytes are crucial to neuron 
microenvironment due to their role in glucose metabolism, blood-brain barrier, neurotransmitter-
uptake, and synaptic development and maturation169-171. Both rodent models and human 
postmortem studies strongly support this hypothesis. For example, rats exposed to maternal 
separation have lower density of astrocytes in the medial prefrontal cortex172, and chronic social 
defeat reduces astrocyte count in various brain regions (prefrontal/frontal cortex, hippocampus 
and amygdala), lowering the levels of GFAP protein, an astrocyte marker173-174. Likewise, 
selective lesion of glial astrocytes by infusing L-α aminoadipic acid into rodent prefrontal cortex 
induces depressive-like behaviors175-176. 
Recently, the role of gut microbiota in affective disorders has been recognized177 to 
modulate multiple neural, endocrine and immune mechanisms178, as shown using germ-free 
animals, bacterial infections or probiotics177. Indeed, germ-free rodents display increased anxiety-
179-180 and depression-like behaviors181, as well as elevated noradrenaline, dopamine and serotonin 
turnover in the striatum182. In contrast, treating germ-free animals with probiotics lowers their 
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anxiety and depression-like behaviors183-185, currently considered as psychobiotics - live 
organisms that, when ingested in adequate amounts, produce a health benefit in patients suffering 
from psychiatric illness186. Complementing gut microbiome involvement, depression is also linked 
to metabolic disorders, especially obesity and diabetes187-192. While the exact mechanisms 
underlying this link remain unclear, some of the linked conditions, such as type 2 diabetes, may 
involve shared pathogenetic mechanisms including chronic activation of immune and 
neuroendocrine parhways192. Animal studies are consistent with clinical data, since the 
Spontaneously Diabetic Torii (SDT) fatty rat model for type 2 diabetes shows increased 
depressive-like behavior, hyperlocomotion, higher basal corticosterone levels, lower serotonin and 
glutamate in prefrontal cortex, and higher GABA and glutamate levels in the hippocampus193. 
Similar depression-like behavior can be observed in diabetes induced by streptozotocin in rats and 
reversed by antidepressant treatment194. Some zebrafish models of diabetes and metabolic 
conditions also evoke anxiety-like behavior195-196. 
4. Conclusion 
Depression-like behavioral phenotypes vary widely between strains and species, and 
therefore cross-strain/species translations of data should be performed carefully197. Furthermore, 
individual differences in animal models also exist, and must be considered198. In fact, rodents 
exhibit a wide population variety in depression-like behaviors, and can be selectively bred for 
depression-like traits (e.g., Flinders Sensitive Line, Swim Low-Active and Helpless Rouen strains) 
26, 199-213. Another important point to consider is environmental characteristics, since 
environmental enrichment and impoverishment can influence individual affective phenotypes214, 
and similar environmental modulation exists in animal depression models215-218. As individual 
differences exist in evolutionarily distant species, such as rodents and zebrafish219-223, individual 
behavioral, genetic and environmental factors must be monitored, to ensure correct interpretation 
of findings. 
Recently, special attention has been given to drugs with putative rapid-acting 
antidepressant effects, affecting even patients resistant to conventional antidepressant treatments. 
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For example, the NMDA receptor antagonist ketamine224 within days reduces depressive 
symptoms225-228 and suicidal thoughts229 in patients, and exerts similar antidepressant effects in 
rodent FST, TST, inflammation-, stress- and learned helplessness-related models230-253.  
Ideally, modeling depression or other mental disorders would need to recreate the etiologic 
process in animals, thus replicating not only specific individual phenotypes of interest, but a wider 
spectrum of neural and behavioral features of the disorder in question254. Given the fact that a 
model by itself is not a perfect replication of the condition studied, not all criteria can be met in a 
single model. Thus, combination of different models can more accurately address the condition of 
interest. Such cross-species paradigm can help understand the most common (and therefore core) 
features of diseases, as well as properly characterize distinct profiles observed in different species. 
Multispecies models of psychiatric diseases can introduce us to a principally new view of diseases 
in which neurobiological constructs play a leading role in pathogenesis. However, such models 
are yet to emerge and will rely on larger and more extensive cross-species studies. 
5. Expert Opinion 
Endophenotype-driven approaches as a locomotive for innovations in the field 
While the lack of understating of pathogenesis of depression and other psychiatric 
disorders slows down further progress in the field, novel approaches continuously emerge255. For 
example, a radical rethinking of current taxonomies is required for deeper understanding of 
psychiatric disorders256-258. Endophenotype strategy reduces complex psychiatric conditions into 
directly measurable neurophysiological, neuropsychological, biochemical, endocrine, 
neuroanatomical or cognitive components259-261. However, this approach is not sufficient to 
overcome limitations that emerge in the field, necessitating further strategies to bridge its 
translational and cross-disciplinary gaps262-264. For example, the “cross-species trait genetic” 
approach postulates that simple behavioral endophenotypes should be conserved between species, 
including humans264. However, the ‘spectrum’ nature of CNS disorders and their overlapping 
endophenotypes, behavioral symptoms and biomarkers should also be considered262-263. 
Addressing this need, the “domain interplay” concept was suggested to further optimize animal 
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modeling of CNS disorders262. Rather than simply focusing on specific behaviors or genes, this 
concept emphasizes the importance of analyzing several overlapping behavioral endophenotypes 
and interplay/dynamics between them262.  
For a rigorous and thorough animal modeling of depression, new approaches also 
necessitate higher-throughput protocols and test batteries265-267. While common strategies utilize 
various specific tests to access key behavioral features of depression, another ‘smart’ approach 
may involve ‘hybrid’ behavioral models to speed up behavioral characterization268. Such 
hybridizing approach assesses several different domains in the same test, or combines several 
single-domain tests in the way that maximizes the spectrum of simultaneously or collectively 
observed phenotypes per trial268. For example, FST may be performed as part of the Morris Water 
maze, a well-established hippocampal memory test, thereby enabling a simultaneous assessment 
of both despair and cognitive responses related to depression268. Likewise, further hybridization 
can be achieved by examining post-swimming self-grooming and locomotor behavior in a 
subsequently run open field (novelty-based) or small observation box, to detect phenotype 
associated with depression-like behavioral perseverations269 and/or examining per-minute 
behavioral activity in these tests, to study habituation (a working memory-related phenotypes) 
reflecting cognitive alterations in depression268, 270. 
Another important aspect to consider is the overall trajectory of the disorder. Indeed, 
neuropsychiatric phenomena are not instant, and cannot be treated separately from their 
development and dynamics 271-272. Albeit markedly understudied, dynamic models in biological 
psychiatry have recently received increasing attention. For example, the ‘interlinking genes’ 
approach can be used to address this problem262-263 since various disordered endophenotypes 
interact with each other, and may share common molecular ‘crosstalk’ mechanisms that, although 
not influencing the phenotypes by themselves, can confer their interrelatedness262-263. Example of 
dynamic interactions in this case can be depression-like phenotypes developing during chronic 
stress after an initial anxiety-like pathological state has occurred. Specifically, the chronic social 
defeat model uses conspecific agonistic interactions between mice (most commonly, C57BL/6J) 
12 
 
to produce a lasting experience of defeat in chronically losing mice273-275. The model is known to 
induce both anxiety-like and depression-like phenotypes276. At the same time, while increased 
anxiety can be observed at 3-10 days of chronic stress277, depression-like phenotype is usually 
induced after 20-21 days of such antagonistic interactions278. Therefore, development of anxiety 
precedes the development of depression in the chronic social stress model; interestingly, this is 
often true for depressed patients, as anxiety can trigger depression in 15-33% of patients278. Thus, 
anxiety states can lead to depression states both clinically and in animal models, and molecular 
and physiological pathways that provide transition between these phenotypes may be promising, 
yet to be identified, drug targets for future therapeutic interventions. 
Another major problem that must be resolved is the apparent lack of coherent long-term 
goals of animal and human disease modeling and CNS drug discovery. For example, the ultimate 
goal of animal tests is to find the most effective therapeutic treatment, without major focus on its 
side effects. In contrast, human tests focus on drug safety much more then on drug efficacy. Like 
cats misread dog behaviors, such conceptual differences in models’ goals produce a well-
documented low yield of CNS drug discovery 279, which not only stifles innovation in this field280, 
but also begins to impact the field in the long-run, as many pharmaceutical giants continue to shut 
down their CNS drug discovery programs, and refocus on other, non-psychiatric diseases281. The 
solution to this problem would be a better synchronization of research goals at pre- and clinical 
stages, for example, by including a drug safety component into preclinical drug discovery testing 
and by focusing more on drug efficacy during pilot clinical studies, with subsequent additional 
trials aimed at reducing drug side effects by testing safer analogs, metabolites or other derivatives 
once the high efficacy of the prototypic drug was established in both pre- and clinical trials. Thus, 
instead of proclaiming a novel promising drug a clinical failure due to its side-effects, a wiser 
strategy would be to screen for its safer compounds first, before making a final determination. 
Thus, the field of antidepressant drug screening can be reinvigorated and innovated, rather than 
suffer a gradual decline and decay. 
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Finally, we want to emphasize that, despite some limitations and complications that animal 
modeling and drug screening in biological psychiatry are facing, the field should not be left behind 
by clinical research. Animal models represent a valuable tool to assess deeply and maximally the 
neurobiological and genetic determinants of disorders. Thus, further innovation of biological 
methodology can complement recent clinical findings, and may soon lead to new comprehensive 
biomedical theories of depression. 
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Figure 2. Use of animal models of depression for 2003-2018, Pubmed searches [species] 
models of depression. In case of fishes, zebrafish, Carassius auratus, goldfish, Poecilia, 
Oryzias, Acipenser, salmon were used. In case of non-human primates, bonobos, 
chimpanzee and macaques were used. (A) Cumulative number of articles per year – can be 
clearly seen superiority of rodents’ models in translational depression research. (B) – 
Relative number of articles per year – was calculated as year n to year 2003 ratio in given 
category and expressed as percent. Can be seen faster relative growth of fish models that 





Table 1. Example of major depression neuropathological subtypes that can be identified2. 
Levels of severity were given depending on most frequent HAMD unit, where 0 — is 
minimal, for anergia, fatigue, insomnias — 2 is maximum, and for anxiety, anhedonia and 
psychomotor retardation 4 is maximum2. 
 
Symptom Severity Biotype 1 Biotype 2 Biotype 3 Biotype 4 
Anhedonia  Moderate Moderate Severe Severe 
Psychomotor retardation Mild Mild Mild Mild 
Anxiety  Moderate Mild Mild Moderate 
Early Insomnia  Severe Mild Severe Severe 
Middle Insomnia  Severe Mild Moderate Severe 





Table 2. Selected examples of rodents’ experimental models of major depression addressing 
distinct aspects of affective pathogenesis. 
Models types Examples and aspect of pathogenesis targeted References 
Stress-related Early-life stress 24, 199, 282-285 
 Social stress 39-40, 60, 62, 81, 
88, 150 
 Aggression 59, 88 
 Chronic stress 35-40 
Genetic Knockouts of the monoaminergic system genes 41-46 
 Knockouts of the HPA-related genes  47-49 
 Selectively bred for helplessness or despair 202-203, 206-208 
Inflammation-related Genetic ablation of inflammation-related genes 50-53 
 Exposure to inflammatory agents, ‘sickness behavior’ 83-86, 91-93 
 Gut microbiota models 180-181, 286 
Monoamine depletion Dopaminergic toxins 37, 77, 81, 137 
 Reserpine-induce 287-288 
Drug abuse-related Chronic treatment with substances of abuse 127, 224 
 Drug withdrawal 54-56 
 




Table 3. Selected non-rodent models for studying neurobiological conditions 
Model Non-human primates Fish 
Stress-induced Chronic stress induced affective disruptions140, 
especially effective are social stress models, 
such as separation122-127 
 
Acute289 or chronic stress148-149, 151, 290 exposure, 
including social stress291, may lead to affective deficits 
and disrupted HPA axis148-149, 151, 289-290 (sensitive to 
antidepressant treatments151) 
Pharmacological G-methyl-p-tyrosine or reserpine may reduce 
social interactions and locomotion, as well as 
induce anhedonia-like lack of environmental 
interaction126, 131 
Repeated intake of psychostimulants provokes behavioral 
sensitization292. Chronic exposure to reserpine293, 
rotenone294 or SiO2 nanoparticles295 evokes depression-
like behaviors 
Genetic Interactions between the serotonin transporter 
gene‐linked polymorphic region (5‐HTTLPR) 
polymorphisms and rearing type have been 
linked to different behaviors associated with 
stress121 
Knockout of the GR gene causes elevation of whole-body 
cortisol levels and changes exploration and habituation 
behavior296-297 
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